Published in J Virol Methods on April 25, 2005
Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog (2010) 2.60
ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proc Natl Acad Sci U S A (2008) 2.48
Assembly and budding of Ebolavirus. PLoS Pathog (2006) 1.62
Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology. Virol J (2006) 1.60
TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. PLoS Pathog (2013) 1.53
The organisation of Ebola virus reveals a capacity for extensive, modular polyploidy. PLoS One (2012) 1.43
Ebola virus VP35-VP40 interaction is sufficient for packaging 3E-5E minigenome RNA into virus-like particles. J Virol (2006) 1.31
Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Cell Microbiol (2009) 1.16
Vaccinating captive chimpanzees to save wild chimpanzees. Proc Natl Acad Sci U S A (2014) 1.12
Viral and host proteins that modulate filovirus budding. Future Virol (2010) 0.93
Advances in virus-like particle vaccines for filoviruses. J Infect Dis (2011) 0.92
Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles. PLoS One (2015) 0.91
Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans. Antiviral Res (2015) 0.78
Ebola VP40 in Exosomes Can Cause Immune Cell Dysfunction. Front Microbiol (2016) 0.77
Integrated Computational Approach for Virtual Hit Identification against Ebola Viral Proteins VP35 and VP40. Int J Mol Sci (2016) 0.75
Strategies in Ebola virus disease (EVD) diagnostics at the point of care. Crit Rev Microbiol (2017) 0.75
Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell (2008) 6.37
Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature (2011) 5.68
Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med (2002) 3.88
Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog (2011) 3.26
Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med (2010) 3.25
Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis (2003) 3.15
Isolation of Mycobacterium tuberculosis mutants defective in the arrest of phagosome maturation. Proc Natl Acad Sci U S A (2004) 2.86
Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis (2007) 2.68
Evaluation of perceived threat differences posed by filovirus variants. Biosecur Bioterror (2011) 2.62
Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem (2006) 2.56
Rotavirus antigenaemia and viraemia: a common event? Lancet (2003) 2.51
Designing a biocontainment unit to care for patients with serious communicable diseases: a consensus statement. Biosecur Bioterror (2006) 2.43
Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc Natl Acad Sci U S A (2005) 2.35
In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc Natl Acad Sci U S A (2003) 2.32
Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A (2003) 2.18
Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J (2012) 2.08
Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog (2006) 2.01
Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection. PLoS Pathog (2012) 2.00
Identification of small molecule inhibitors of anthrax lethal factor. Nat Struct Mol Biol (2003) 1.86
Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis (2005) 1.82
The evolving field of biodefence: therapeutic developments and diagnostics. Nat Rev Drug Discov (2005) 1.79
Dendritic cells endocytose Bacillus anthracis spores: implications for anthrax pathogenesis. J Immunol (2005) 1.78
Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol (2008) 1.78
Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol (2005) 1.69
Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains. Antimicrob Agents Chemother (2009) 1.66
VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother (2006) 1.63
Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol (2009) 1.62
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol (2012) 1.59
Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol (2004) 1.58
3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells. Proc Natl Acad Sci U S A (2010) 1.52
Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J Virol (2010) 1.48
P2X7 receptor cell surface expression and cytolytic pore formation are regulated by a distal C-terminal region. J Biol Chem (2002) 1.48
Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J Biol Chem (2006) 1.47
Mechanical tension can specify axonal fate in hippocampal neurons. J Cell Biol (2002) 1.46
Time-lapse confocal imaging of development of Bacillus anthracis in macrophages. J Infect Dis (2004) 1.44
Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med (2004) 1.44
Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine (2005) 1.44
Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J Infect Dis (2012) 1.40
IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. J Virol (2013) 1.39
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One (2013) 1.38
Anthrax biosensor, protective antigen ion channel asymmetric blockade. J Biol Chem (2005) 1.37
Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem Biophys Res Commun (2003) 1.34
Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit. Emerg Infect Dis (2008) 1.30
Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol J (2007) 1.30
Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection. PLoS One (2012) 1.28
Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis. PLoS Pathog (2013) 1.28
Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clin Immunol (2003) 1.27
Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother (2009) 1.26
Assembly of a functional Machupo virus polymerase complex. Proc Natl Acad Sci U S A (2010) 1.24
Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses (2012) 1.23
Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines (2008) 1.23
Ebola virus uses clathrin-mediated endocytosis as an entry pathway. Virology (2010) 1.23
Novel structurally designed vaccine for S. aureus α-hemolysin: protection against bacteremia and pneumonia. PLoS One (2012) 1.20
Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine (2004) 1.19
Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates. Antimicrob Agents Chemother (2010) 1.18